Skip to main content
Top
Published in: Current Heart Failure Reports 2/2024

Open Access 01-02-2024 | Heart Failure | Review

Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions—Part II: Combination Therapy

Authors: Cuthbert J.J, Cleland J.G.F, Clark A.L

Published in: Current Heart Failure Reports | Issue 2/2024

Login to get access

Abstract

Purpose of Review

Fluid retention or congestion is a major cause of symptoms, poor quality of life, and adverse outcome in patients with heart failure (HF). Despite advances in disease-modifying therapy, the mainstay of treatment for congestion—loop diuretics—has remained largely unchanged for 50 years. In these two articles (part I: loop diuretics and part II: combination therapy), we will review the history of diuretic treatment and current trial evidence for different diuretic strategies and explore potential future directions of research.

Recent Findings

We will assess recent trials, including DOSE, TRANSFORM, ADVOR, CLOROTIC, OSPREY-AHF, and PUSH-AHF, and assess how these may influence current practice and future research.

Summary

There are few data on which to base diuretic therapy in clinical practice. The most robust evidence is for high-dose loop diuretic treatment over low-dose treatment for patients admitted to hospital with HF, yet this is not reflected in guidelines. There is an urgent need for more and better research on different diuretic strategies in patients with HF.
Literature
5.
go back to reference Neuberg GW, Miller AB, O’Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M. PRAISE Investigators. Prospective randomized amlodipine survival evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144(1):31–8. https://doi.org/10.1067/mhj.2002.123144.CrossRefPubMed Neuberg GW, Miller AB, O’Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M. PRAISE Investigators. Prospective randomized amlodipine survival evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144(1):31–8. https://​doi.​org/​10.​1067/​mhj.​2002.​123144.CrossRefPubMed
6.•
go back to reference Trulls JC, Morales-Rull JL, Casado J, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. 2023;44(5):411–21. RCT of hydrochlorothiazide in patients hospitalised with heart failureCrossRef Trulls JC, Morales-Rull JL, Casado J, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J. 2023;44(5):411–21. RCT of hydrochlorothiazide in patients hospitalised with heart failureCrossRef
8.
go back to reference Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713–22.PubMedCrossRef Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail. 2020;22(4):713–22.PubMedCrossRef
9.
go back to reference Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H, Haught WH, Wagoner L, Gupta D, Patten R, Gordon P, Korr K, Fileccia R, Pressler SJ, Gregory D, Wedge P, Dowling D, Romeling M, Konstam JM, Massaro JM, Udelson JE. SECRET of CHF Investigators, Coordinators, and Committee Members. Short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol. 2017;69(11):1409–19.PubMedCrossRef Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H, Haught WH, Wagoner L, Gupta D, Patten R, Gordon P, Korr K, Fileccia R, Pressler SJ, Gregory D, Wedge P, Dowling D, Romeling M, Konstam JM, Massaro JM, Udelson JE. SECRET of CHF Investigators, Coordinators, and Committee Members. Short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol. 2017;69(11):1409–19.PubMedCrossRef
10.
go back to reference Paterna S, Fasullo S, Parrinello G, et al. Short-term effects of hypertonic saline solution in acute heart failure and long-term effects of a moderate sodium restriction in patients with compensated heart failure with New York Heart Association class III (Class C) (SMAC-HF Study). Am J Med Sci. 2011;342(1):27–37.PubMedCrossRef Paterna S, Fasullo S, Parrinello G, et al. Short-term effects of hypertonic saline solution in acute heart failure and long-term effects of a moderate sodium restriction in patients with compensated heart failure with New York Heart Association class III (Class C) (SMAC-HF Study). Am J Med Sci. 2011;342(1):27–37.PubMedCrossRef
11.
go back to reference Montgomery RA, Mauch J, Sankar P, et al. Oral sodium to preserve renal efficiency in acute heart failure: a randomized, placebo-controlled, double-blind study [published online ahead of print. J Card Fail. 2023;S1071–9164(23)00111–2 (RCT of oral salt supplements in patients admitted to hospital with heart failure) Montgomery RA, Mauch J, Sankar P, et al. Oral sodium to preserve renal efficiency in acute heart failure: a randomized, placebo-controlled, double-blind study [published online ahead of print. J Card Fail. 2023;S1071–9164(23)00111–2 (RCT of oral salt supplements in patients admitted to hospital with heart failure)
13.
go back to reference McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart. J Eur Heart J. 2021;42(36):3599–726.PubMedCrossRef McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [published correction appears in Eur Heart. J Eur Heart J. 2021;42(36):3599–726.PubMedCrossRef
16.
go back to reference McCallum W, Tighiouart H, Testani JM, et al. Rates of reversal of volume overload in hospitalized acute heart failure: association with long-term kidney function. Am J Kidney Dis. 2022;80(1):65–78.PubMedCrossRef McCallum W, Tighiouart H, Testani JM, et al. Rates of reversal of volume overload in hospitalized acute heart failure: association with long-term kidney function. Am J Kidney Dis. 2022;80(1):65–78.PubMedCrossRef
18.
go back to reference Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56(19):1527–34.PubMedCrossRef Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56(19):1527–34.PubMedCrossRef
21.
34.
go back to reference Doggrell SA. Tolvaptan (Otsuka). Curr Opin Investig Drugs. 2004;5(9):977–83.PubMed Doggrell SA. Tolvaptan (Otsuka). Curr Opin Investig Drugs. 2004;5(9):977–83.PubMed
35.
go back to reference Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332–43. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332–43.
36.
go back to reference Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M, Patel CB, Echols M, Khouri MG, Tauras JM, Gupta D, Monds P, Roberts R, O’Connor CM. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69(11):1399–406.PubMedCrossRef Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M, Patel CB, Echols M, Khouri MG, Tauras JM, Gupta D, Monds P, Roberts R, O’Connor CM. Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69(11):1399–406.PubMedCrossRef
39.
go back to reference Katz AI. Renal Na-K-ATPase: its role in tubular sodium and potassium transport. Am J Physiol. 1982;242(3):F207–19.PubMed Katz AI. Renal Na-K-ATPase: its role in tubular sodium and potassium transport. Am J Physiol. 1982;242(3):F207–19.PubMed
42.
go back to reference Pamnani MB, Chen S, Bryant HJ, et al. Effects of three sodium-potassium adenosine triphosphatase inhibitors. Hypertension. 1991;18(3):316–24.PubMedCrossRef Pamnani MB, Chen S, Bryant HJ, et al. Effects of three sodium-potassium adenosine triphosphatase inhibitors. Hypertension. 1991;18(3):316–24.PubMedCrossRef
43.
47.
49.
go back to reference Damjancic P, Vierhapper H. Permissive action of glucocorticoid substitution therapy on the effects of atrial natriuretic peptide (hANP) in patients with adrenocortical insufficiency. Exp Clin Endocrinol. 1990;95(3):315–21.PubMedCrossRef Damjancic P, Vierhapper H. Permissive action of glucocorticoid substitution therapy on the effects of atrial natriuretic peptide (hANP) in patients with adrenocortical insufficiency. Exp Clin Endocrinol. 1990;95(3):315–21.PubMedCrossRef
50.
go back to reference Garcia R, Debinski W, Gutkowska J, et al. Gluco- and mineralocorticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo. Biochem Biophys Res Commun. 1985;131(2):806–14.PubMedCrossRef Garcia R, Debinski W, Gutkowska J, et al. Gluco- and mineralocorticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo. Biochem Biophys Res Commun. 1985;131(2):806–14.PubMedCrossRef
51.
go back to reference Liu C, Chen Y, Kang Y, et al. Glucocorticoids improve renal responsiveness to atrial natriuretic peptide by up-regulating natriuretic peptide receptor-A expression in the renal inner medullary collecting duct in decompensated heart failure. J Pharmacol Exp Ther. 2011;339(1):203–9.PubMedCrossRef Liu C, Chen Y, Kang Y, et al. Glucocorticoids improve renal responsiveness to atrial natriuretic peptide by up-regulating natriuretic peptide receptor-A expression in the renal inner medullary collecting duct in decompensated heart failure. J Pharmacol Exp Ther. 2011;339(1):203–9.PubMedCrossRef
52.
go back to reference Lanier-Smith KL, Currie MG. Effect of glucocorticoids on the binding of atrial natriuretic peptide to endothelial cells. Eur J Pharmacol. 1990;178(1):105–9.PubMedCrossRef Lanier-Smith KL, Currie MG. Effect of glucocorticoids on the binding of atrial natriuretic peptide to endothelial cells. Eur J Pharmacol. 1990;178(1):105–9.PubMedCrossRef
53.
go back to reference Liu C, Guan J, Kang Y, et al. Inhibition of dehydration-induced water intake by glucocorticoids is associated with activation of hypothalamic natriuretic peptide receptor-A in rat. PLoS ONE. 2010;5(12):e15607.ADSPubMedPubMedCentralCrossRef Liu C, Guan J, Kang Y, et al. Inhibition of dehydration-induced water intake by glucocorticoids is associated with activation of hypothalamic natriuretic peptide receptor-A in rat. PLoS ONE. 2010;5(12):e15607.ADSPubMedPubMedCentralCrossRef
54.
go back to reference Genest J, Cantin M. Atrial natriuretic factor. Circulation. 1987;75(1 Pt 2):I118–24.PubMed Genest J, Cantin M. Atrial natriuretic factor. Circulation. 1987;75(1 Pt 2):I118–24.PubMed
55.
go back to reference Gutkowska J, Antunes-Rodrigues J, McCann SM. Atrial natriuretic peptide in brain and pituitary gland. Physiol Rev. 1997;77(2):465–515.PubMedCrossRef Gutkowska J, Antunes-Rodrigues J, McCann SM. Atrial natriuretic peptide in brain and pituitary gland. Physiol Rev. 1997;77(2):465–515.PubMedCrossRef
57.
go back to reference Baylis C, Brenner BM. Mechanism of the glucocorticoid-induced increase in glomerular filtration rate. Am J Physiol. 1978;234(2):F166–70.PubMed Baylis C, Brenner BM. Mechanism of the glucocorticoid-induced increase in glomerular filtration rate. Am J Physiol. 1978;234(2):F166–70.PubMed
58.
go back to reference Baylis C, Handa RK, Sorkin M. Glucocorticoids and control of glomerular filtration rate. Semin Nephrol. 1990;10(4):320–9.PubMed Baylis C, Handa RK, Sorkin M. Glucocorticoids and control of glomerular filtration rate. Semin Nephrol. 1990;10(4):320–9.PubMed
59.
go back to reference de Matteo R, May CN. Inhibition of prostaglandin and nitric oxide synthesis prevents cortisol-induced renal vasodilatation in sheep. Am J Physiol. 1999;276(4):R1125–31.PubMed de Matteo R, May CN. Inhibition of prostaglandin and nitric oxide synthesis prevents cortisol-induced renal vasodilatation in sheep. Am J Physiol. 1999;276(4):R1125–31.PubMed
60.
go back to reference De Matteo R, May CN. Glucocorticoid-induced renal vasodilatation is mediated by a direct renal action involving nitric oxide. Am J Physiol. 1997;273(6):R1972–9.PubMed De Matteo R, May CN. Glucocorticoid-induced renal vasodilatation is mediated by a direct renal action involving nitric oxide. Am J Physiol. 1997;273(6):R1972–9.PubMed
61.
go back to reference Bednarik JA, May CN. Differential regional hemodynamic effects of corticotropin in conscious sheep. Hypertension. 1994;24(1):49–55.PubMedCrossRef Bednarik JA, May CN. Differential regional hemodynamic effects of corticotropin in conscious sheep. Hypertension. 1994;24(1):49–55.PubMedCrossRef
62.
go back to reference Aguirre JA, Ibarra FR, Barontini M, Arrizurieta EE, Armando I. Effect of glucocorticoids on renal dopamine production. Eur J Pharmacol. 1999;370(3):271–8.PubMedCrossRef Aguirre JA, Ibarra FR, Barontini M, Arrizurieta EE, Armando I. Effect of glucocorticoids on renal dopamine production. Eur J Pharmacol. 1999;370(3):271–8.PubMedCrossRef
64.
go back to reference Liu C, Liu G, Zhou C, Ji Z, Zhen Y, Liu K. Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance. Can J Cardiol. 2007;23(11):865–8.PubMedPubMedCentralCrossRef Liu C, Liu G, Zhou C, Ji Z, Zhen Y, Liu K. Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance. Can J Cardiol. 2007;23(11):865–8.PubMedPubMedCentralCrossRef
65.
go back to reference Zhang H, Liu C, Ji Z, et al. Prednisone adding to usual care treatment for refractory decompensated congestive heart failure. Int Heart J. 2008;49(5):587–95.PubMedCrossRef Zhang H, Liu C, Ji Z, et al. Prednisone adding to usual care treatment for refractory decompensated congestive heart failure. Int Heart J. 2008;49(5):587–95.PubMedCrossRef
66.
go back to reference Liu C, Chen H, Zhou C, et al. Potent potentiating diuretic effects of prednisone in congestive heart failure. J Cardiovasc Pharmacol. 2006;48(4):173–6.PubMedCrossRef Liu C, Chen H, Zhou C, et al. Potent potentiating diuretic effects of prednisone in congestive heart failure. J Cardiovasc Pharmacol. 2006;48(4):173–6.PubMedCrossRef
67.
go back to reference Liu C, Liu K; COPE-ADHF Study Group. Cardiac outcome prevention effectiveness of glucocorticoids in acute decompensated heart failure: COPE-ADHF study. J Cardiovasc Pharmacol. 2014;63(4):333–8.CrossRef Liu C, Liu K; COPE-ADHF Study Group. Cardiac outcome prevention effectiveness of glucocorticoids in acute decompensated heart failure: COPE-ADHF study. J Cardiovasc Pharmacol. 2014;63(4):333–8.CrossRef
69.
70.
go back to reference McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group. focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;25:195. https://doi.org/10.1093/eurheartj/ehad195.CrossRef McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group. focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;25:195. https://​doi.​org/​10.​1093/​eurheartj/​ehad195.CrossRef
71.
go back to reference Miller WL, Borgeson DD, Grantham JA, Luchner A, Redfield MM, Burnett JC Jr. Dietary sodium modulation of aldosterone activation and renal function during the progression of experimental heart failure. Eur J Heart Fail. 2015;17(2):144–50.PubMedCrossRef Miller WL, Borgeson DD, Grantham JA, Luchner A, Redfield MM, Burnett JC Jr. Dietary sodium modulation of aldosterone activation and renal function during the progression of experimental heart failure. Eur J Heart Fail. 2015;17(2):144–50.PubMedCrossRef
73.
go back to reference Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial [published correction appears in Lancet. Lancet. 2022;399(10333):1391–400.PubMedCrossRef Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial [published correction appears in Lancet. Lancet. 2022;399(10333):1391–400.PubMedCrossRef
74.
go back to reference Aliti GB, Rabelo ER, Clausell N, Rohde LE, Biolo A, Beck-da-Silva L. Aggressive fluid and sodium restriction in acute decompensated heart failure: a randomized clinical trial. JAMA Intern Med. 2013;173(12):1058–64.PubMedCrossRef Aliti GB, Rabelo ER, Clausell N, Rohde LE, Biolo A, Beck-da-Silva L. Aggressive fluid and sodium restriction in acute decompensated heart failure: a randomized clinical trial. JAMA Intern Med. 2013;173(12):1058–64.PubMedCrossRef
75.
go back to reference Gandhi S, Mosleh W, Myers RB. Hypertonic saline with furosemide for the treatment of acute congestive heart failure: a systematic review and meta-analysis. Int J Cardiol. 2014;173(2):139–45.PubMedCrossRef Gandhi S, Mosleh W, Myers RB. Hypertonic saline with furosemide for the treatment of acute congestive heart failure: a systematic review and meta-analysis. Int J Cardiol. 2014;173(2):139–45.PubMedCrossRef
76.
go back to reference Maleki M, Nematbakhsh M. Renal blood flow response to angiotensin 1–7 versus hypertonic sodium chloride 7.5% administration after acute hemorrhagic shock in rats. Int J Vasc Med. 2016;2016:6562017.PubMedPubMedCentral Maleki M, Nematbakhsh M. Renal blood flow response to angiotensin 1–7 versus hypertonic sodium chloride 7.5% administration after acute hemorrhagic shock in rats. Int J Vasc Med. 2016;2016:6562017.PubMedPubMedCentral
77.
go back to reference Kien ND, Reitan JA, White DA, Wu CH, Eisele JH. Cardiac contractility and blood flow distribution following resuscitation with 7.5% hypertonic saline in anesthetized dogs. Circ Shock. 1991;35(2):109–16.PubMed Kien ND, Reitan JA, White DA, Wu CH, Eisele JH. Cardiac contractility and blood flow distribution following resuscitation with 7.5% hypertonic saline in anesthetized dogs. Circ Shock. 1991;35(2):109–16.PubMed
79.
go back to reference Vaklotton MB, Davison JM, Riondel AM, Lindheimer MD. Response of the renin-aldosterone system and antidiuretic hormone to oral water loading and hypertonic saline infusion during and after pregnancy. Clin Exp Hypertens B. 1982;1(2–3):385–400.PubMed Vaklotton MB, Davison JM, Riondel AM, Lindheimer MD. Response of the renin-aldosterone system and antidiuretic hormone to oral water loading and hypertonic saline infusion during and after pregnancy. Clin Exp Hypertens B. 1982;1(2–3):385–400.PubMed
80.
go back to reference Paterna S, Di Pasquale P, Parrinello G, et al. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol. 2005;45(12):1997–2003. https://doi.org/10.1016/j.jacc.2005.01.059.CrossRefPubMed Paterna S, Di Pasquale P, Parrinello G, et al. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol. 2005;45(12):1997–2003. https://​doi.​org/​10.​1016/​j.​jacc.​2005.​01.​059.CrossRefPubMed
84.
go back to reference Madieh J, Hasan B, Khamayseh I, et al. The safety of intravenous peripheral administration of 3% hypertonic saline: a systematic review and meta-analysis. Am J Med Sci. 2023;366(2):135–42.PubMedCrossRef Madieh J, Hasan B, Khamayseh I, et al. The safety of intravenous peripheral administration of 3% hypertonic saline: a systematic review and meta-analysis. Am J Med Sci. 2023;366(2):135–42.PubMedCrossRef
86.
go back to reference Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, et al. ESC heart failure long-term registry investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC heart failure long-term registry. Eur J Heart Fail. 2017;19:1242–54.PubMedCrossRef Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, et al. ESC heart failure long-term registry investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC heart failure long-term registry. Eur J Heart Fail. 2017;19:1242–54.PubMedCrossRef
87.
go back to reference Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, et al. ESC-EORP-HFA heart failure long-term registry investigators. Acute heart failure congestion and perfusion status – impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019;21:1338–52.PubMedCrossRef Chioncel O, Mebazaa A, Maggioni AP, Harjola VP, Rosano G, Laroche C, et al. ESC-EORP-HFA heart failure long-term registry investigators. Acute heart failure congestion and perfusion status – impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019;21:1338–52.PubMedCrossRef
88.
go back to reference Rubio-Gracia J, Demissei BG, Ter Maaten JM, et al. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol. 2018;258:185–91.PubMedCrossRef Rubio-Gracia J, Demissei BG, Ter Maaten JM, et al. Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. Int J Cardiol. 2018;258:185–91.PubMedCrossRef
89.
go back to reference Pellicori P, Shah P, Cuthbert J, et al. Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure. Eur J Heart Fail. 2019;21(7):904–16.PubMedCrossRef Pellicori P, Shah P, Cuthbert J, et al. Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure. Eur J Heart Fail. 2019;21(7):904–16.PubMedCrossRef
92.
go back to reference Mor A, Thomsen RW, Ulrichsen SP, Sørensen HT. Chronic heart failure and risk of hospitalization with pneumonia: a population-based study. Eur J Intern Med. 2013;24(4):349–53.PubMedCrossRef Mor A, Thomsen RW, Ulrichsen SP, Sørensen HT. Chronic heart failure and risk of hospitalization with pneumonia: a population-based study. Eur J Intern Med. 2013;24(4):349–53.PubMedCrossRef
93.
go back to reference Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013;15:1082–94.PubMedCrossRef Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2013;15:1082–94.PubMedCrossRef
94.•
go back to reference Burns DJP, Arora J, Okunade O, Beltrame JF, Bernardez-Pereira S, Crespo-Leiro MG, et al. International consortium for health outcomes measurement (ICHOM): standardized patient-centered outcomes measurement set for heart failure patients. JACC Heart Fail. 2020;8:212–22. https://doi.org/10.1016/j.jchf.2019.09.007. Important consensus document on patient related outcome measures in clinical trials of acute heart failureCrossRefPubMedPubMedCentral Burns DJP, Arora J, Okunade O, Beltrame JF, Bernardez-Pereira S, Crespo-Leiro MG, et al. International consortium for health outcomes measurement (ICHOM): standardized patient-centered outcomes measurement set for heart failure patients. JACC Heart Fail. 2020;8:212–22. https://​doi.​org/​10.​1016/​j.​jchf.​2019.​09.​007. Important consensus document on patient related outcome measures in clinical trials of acute heart failureCrossRefPubMedPubMedCentral
Metadata
Title
Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions—Part II: Combination Therapy
Authors
Cuthbert J.J
Cleland J.G.F
Clark A.L
Publication date
01-02-2024
Publisher
Springer US
Published in
Current Heart Failure Reports / Issue 2/2024
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-024-00644-2

Other articles of this Issue 2/2024

Current Heart Failure Reports 2/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine